SCHEMBL7532145

SCHEMBL7532145

C[C@H](CCO)CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5501839 1.00
SCHEMBL12287911 1.00
SCHEMBL8009888 0.89 TSHR (0.44)
SCHEMBL9974590 0.86 BHMT (0.52)
SCHEMBL9460828 0.85 BHMT (0.44)
SCHEMBL426173 0.85 BHMT (0.44)
SCHEMBL18704287 0.85 BHMT (0.44)
SCHEMBL8569864 0.83 BHMT (0.43)
Ethylene Glycol SCHEMBL10361806 0.83 GABRP (0.48)
Toluene SCHEMBL28231458 0.82 TRPA1 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180941-A1 ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-06-06 US disclosed
US-11813272-B2 Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2023-11-14 US disclosed
US-20230293458-A1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2023-09-21 US disclosed
US-20210177877-A1 ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2021-06-17 US disclosed
US-10953027-B2 Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2021-03-23 US disclosed
US-20200197428-A1 ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE FLAGSHIP PIONEERING, INC. 2020-06-25 US disclosed
US-20200101030-A1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME KINTAI THERAPEUTICS, INC. 2020-04-02 US disclosed
EP-2498605-B1 DIURETICS MERCK SHARP & DOHME (US) 2014-08-27 EP disclosed
CN-102167666-B Method for synthesizing high-enantiomer-purity diprionidae pheromone and stereo isomer UNIV XIAMEN 2013-09-18 CN disclosed
US-8354394-B2 Diuretics MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120208838-A1 DIURETICS MERCK SHARP & DOHME LLC 2012-08-16 US disclosed
CN-102167666-A Method for synthesizing high-enantiomer-purity diprionidae pheromone and stereo isomer UNIV XIAMEN 2011-08-31 CN disclosed
CN-101210258-A Method for preparing (R)-3-hydroxyethyl butyrate by microorganism conversion UNIV ZHEJIANG TECHNOLOGY (CN) 2008-07-02 CN disclosed
CN-1205250-C Polymerization of ethylene oxide using metal cyanide catalysts DOW GLOBAL TECHNOLOGY INC (US) 2005-06-08 CN disclosed
CN-1360607-A Polymerization of ethylene oxide using metal cyanide catalysts DOW CHEMICAL CO (US) 2002-07-24 CN disclosed
EP-1188749-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATE COMPOUNDS OF DRUGS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-03-20 EP disclosed